Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Altimmune (ALT – Research Report) today and set a price target of $25.00. The company’s shares closed yesterday at $9.01.
According to TipRanks, Rahimi is a 4-star analyst with an average return of 9.9% and a 39.95% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Crinetics Pharmaceuticals, and CymaBay Therapeutics.
Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $21.29, representing a 136.29% upside. In a report released on February 13, B.Riley Financial also reiterated a Buy rating on the stock with a $20.00 price target.
See the top stocks recommended by analysts >>
ALT market cap is currently $484.1M and has a P/E ratio of -5.87.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Altimmune (ALT) Company Description:
The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.
Read More on ALT:
- Altimmune short report includes ‘factual inconsistencies,’ says B. Riley
- Altimmune down 16% after Kerrisdale short report
- Short Altimmune ahead of pemvidutide Phase 3 ‘bomb,’ says Kerrisdale
- Kerrisdale Capital says short Altimmune, says only drug ‘going to bomb’
- Altimmune call volume above normal and directionally bullish
